| Objective:The Coronary atherosclerotic heart disease,or Coronary heart disease(CHD)is due to coronary atherosclerosis narrowing or obstruction of the vascular cavity,or coronary artery function changes,resulting in myocardial ischemia or necrosis caused by heart disease.The disease is a common clinical heart disease.Unstable angina,which is between the stable angina and acute myocardial infarction clinical condition,with stable angina pectoris Compared adverse cardiovascular events in patients with unstable angina recurrence rate significantly increased.Research shows that lipid disorder and inflammatory response are important pathologic mechanisms in the development of coronary heart disease and unstable angina pectoris.This drug is commonly used to treat hyperlipidemia,but it has less research on inflammatory factors.This study through research the combination of the HeDan tablet with rishuvastain effect of the treatment of unstable angina pectoris on blood lipids and the intervention of inflammatory cytokines,provide the basis for the clinical application of the drug better.Methods:With reference to the International Society for Heart Disease and the World Health Oganization task force on standardization of clinical nomenclature report The Naming of Ischemic Heart Disease and Diagnostic of Coronary Heart Disease Standards and the Chinese Medical Association Cardiovascular Disease Editorial Board of the Unstable Angina and Non-st-segment Elevation Myocardial Ifarction Diagnosis and Treatment Guidelines relevant diagnostic criteria,and collected effective cases of 128 patients with unstable angina.There were 62 cases in the treatment group,40 males and 22 females.with an average age of(63.42±9.96)years.The course of the disease is from 7 months to 8 years.There were 66 cases in the control group,including 42 males and 24 females.The average age was(65.67±8.35)years and the course was 10 months to 6 years.The statistical treatment showed that there was no statistically significant difference(P>0.05)between the two groups in terms of gender,age,duration and Braunwald classification.So it's comparable.In this study,a random digital table method was used to randomly design.The treatment group was given Hedan tablet combined with resuvastatin orally.The Hedan tablet is provided by Nanchang Jishun Pharmaceutical co.,Ltd.Two tablets,three times a day,before meals;Rishuvastatin calcium tablet is provided by Zhejiang Jingxin Pharmaceutical Co.,Ltd.Take oral 20 mg per night,one day at a time.Control group only oral reshuvastatin calcium tablet.The two group were treated for there months.After the treatment,the number of angina pectoris and the change of duration were observed.Two groups of patients before and after treatment,morning fasting venous blood was drawn 5ml,using automatic biochemical analyzer to determine patients serum total cholesterol(TC).triglycerides(TG).low-density lipoprotein cholestrerol(LDL-C)and high-density lipoprotein cholesterol(HDL-C);Two groups of patients before and after treatment,morning fasting venous blood was drawn 5ml,Anticoagulation,Centrifuge to remove the liquid,Keep it in the refrigerator at-20?.The level of hypersensitive C-reactive protein(Hs-CRP)was determined by immune-scattering method.The level of interleukin(IL-6)and tumor necrosis factor ?(TNF-?)were determined by the radioimmunoassay.Hs-CRP testing kit is provided by Beijing northern biotechnology research institute,TNF-? and IL-6 free kit is provided by Beijing institute of east Asian immunization technology,The SN-9 full-automatic dual-probe radioimmunity ? counter is provided by the upper nuclear sun ring provide photoelectric instrument co.,LTD;After the treatment of two groups of patients,the clinical efficacy of two groups of patients was judged by referring to the criteria for the treatment of Guidelines on the clinical research of new Chinese medicine drugs.The data was processed by SPSS for Windows 20.0 Statistical Software,and the standara of hypothesis testing was 0.05.The average number of measurement data is plus or minus standard deviation(±s).The statistical method was used to test the t test with paired t test and two sets of independent samples;Rank and test are used for grade data;Count data with ?2 inspection.Results:1.Comparison of the number of angina pectoris and duration of the two groups of patients before and after treatment.There was no statistically significant difference between the number of angina pectoris and the duration of the duration of the two groups(P>0.5).Compared with the treatment before treatment,the number of angina attacks in the two groups was significantly reduced,and the duration of the attack was significantly shortened,with statistical difference(P<0.01);After treatment,the angina pectoris was less than the control group,and the duration of the attack was shorter than the control group,and there was a statistical difference(P<0.05).2.Comparison of blood lipid changes before and after treatment in two groups.Before treatment,TG,TC,LDL-C and HDL-C were not statistically significant(P>0.05);After treatment,TG,TC and LDL-C were significantly reduced in both groups,with statistically significant differences(P<0.05),After treatment,the HDL-C content was significantly higher than before,with statistical difference(P<0.05),while the control group was not significantly changed;After treatment,TG and LDL-C's level were significantly lower than the control group,with statistical difference(P<0.05).3.The comparison of serum inflammatory factors Hs-CRP,TNF-? and IL-6 content in the two groups was compared.There was no statistically significant difference(P>0.05)between the two groups in the treatment of pretreatment Hs-CRP?TNF-? and IL-6.After treatment,Hs-CRP ? TNF-? ? IL-6 were significantly reduced in both groups,with statistically significant differences(P<0.05),After treatment,Hs-CRP and TNF-? were significantly lower than the control group,with statistical difference(P<0.05).4 Comparison of clinical efficacy of UA in two groups of patients.The total effective rate of treatment group was 90.3%,and the total effective rate of control group was 77.3%,compared with the two groups,the total effective rate of treatment group was better than that of the control group(P<0.05)Conclusion:1.Hedan tablet combined with resuvastatin calcium tablet can obviously decrease the times of UA patients with angina and shorten the duration,improve clinical symptoms,the clinical total effective rate was 90.3%,the curative effect is superior to pure application of resuvastatin calcium tablet.2.Hedan tablet combined with resuvastatin calcium tablet can significantly reduce TG,TC,and LDL-C levels,indicating that regulating blood lipid levels is one of the mechanisms for treating UA.3.Hedan tablet combined with resuvastatin calcium tablet can significantly reduce the serum inflammatory factors Hs-CRP?TNF-??IL-6 content,indicating that the regulation of inflammatory factor level is one of the mechanism of the treatment of UA. |
PDF Full Text Request